Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gentien

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Plos One|October 19, 2017
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancersDelphine Hequet, Céline Callens, David Gentien, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
Current Oncology (Toronto, Ont.)|October 27, 2023
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility StudyFariba Nemati, Leanne de Koning, David Gentien, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 RetrotransposonsMarc Michel, Maryam Heidary, Anissa Mechri, et al.
NPJ Precision Oncology|June 24, 2021
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trialIstvan Petak, Maud Kamal, Anna Dirner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast CancersElisabetta Marangoni, Cécile Laurent, Florence Coussy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in NeuroblastomaMathieu Chicard, Sandrine Boyault, Leo Colmet Daage, et al.
International Journal of Cancer|March 13, 2019
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancerFlorence Coussy, Leanne de Koning, Marion Lavigne, et al.
The Lancet. Oncology|February 25, 2018
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohortsSarah Huet, Bruno Tesson, Jean-Philippe Jais, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Plos One|October 19, 2017
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancersDelphine Hequet, Céline Callens, David Gentien, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
Current Oncology (Toronto, Ont.)|October 27, 2023
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility StudyFariba Nemati, Leanne de Koning, David Gentien, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 RetrotransposonsMarc Michel, Maryam Heidary, Anissa Mechri, et al.
NPJ Precision Oncology|June 24, 2021
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trialIstvan Petak, Maud Kamal, Anna Dirner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast CancersElisabetta Marangoni, Cécile Laurent, Florence Coussy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in NeuroblastomaMathieu Chicard, Sandrine Boyault, Leo Colmet Daage, et al.
International Journal of Cancer|March 13, 2019
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancerFlorence Coussy, Leanne de Koning, Marion Lavigne, et al.
The Lancet. Oncology|February 25, 2018
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohortsSarah Huet, Bruno Tesson, Jean-Philippe Jais, et al.
Pageof 9